Bridging with Enoxaparin Before Left Heart Catheterization
For patients on warfarin requiring left heart catheterization, bridging with enoxaparin is generally NOT recommended unless the patient has high thrombotic risk (CHADS₂ score ≥5, mechanical heart valve, or recent stroke/TIA within 3 months). Most patients undergoing diagnostic or interventional cardiac catheterization can safely have warfarin interrupted without bridging therapy.
When Bridging IS Indicated (High Thrombotic Risk Only)
Stop warfarin 5 days before the procedure 1, 2. Begin therapeutic-dose enoxaparin when INR falls below therapeutic range (typically 2-3 days after stopping warfarin):
Standard Bridging Dosing:
- 1 mg/kg subcutaneous every 12 hours 3, 4, 5
- Last dose: Morning of the day BEFORE the procedure (approximately 24 hours pre-procedure) at half the total daily dose 1, 2
- This timing is critical—giving the evening dose before surgery leaves excessive anticoagulant activity at procedure time 6
Renal Dose Adjustments:
- CrCl <30 mL/min: 1 mg/kg once daily 3, 7, 4, 7
- Consider UFH instead in severe renal impairment due to shorter half-life and reversibility 8
At the Time of Catheterization
If the patient arrives on enoxaparin, additional dosing depends on timing 3, 4:
- Last dose <8 hours ago: No additional enoxaparin needed
- Last dose 8-12 hours ago OR only 1 prior dose given: Give 0.3 mg/kg IV bolus
- No prior enoxaparin: Give 0.5-0.75 mg/kg IV bolus
The 2025 ACC/AHA/SCAI guidelines specifically address enoxaparin use during PCI, noting it may be considered as an alternative to UFH to reduce ischemic events 4.
Post-Procedure Resumption
- Resume warfarin: Evening of procedure (day 0) or next day at usual maintenance dose 1, 2
- Resume enoxaparin:
- Continue bridging until INR therapeutic for 2 consecutive days 9
Critical Caveats
Most patients do NOT need bridging. The 2022 ACCP guidelines emphasize that bridging should be reserved for truly high-risk patients 1, 2. Left heart catheterization, whether diagnostic or interventional, is typically performed with minimal interruption of anticoagulation.
For atrial fibrillation patients with lower risk (CHADS₂ <5, no mechanical valve, no recent stroke), simply stopping warfarin 5 days before and resuming within 24 hours post-procedure without bridging is the preferred approach 10, 1.
Never switch between enoxaparin and UFH during the same episode—this significantly increases bleeding risk 7.
Check INR before the procedure to ensure <1.5 for safe procedural anticoagulation 10, 1.
The evidence shows that bridging with full-dose LMWH increases bleeding risk without clear reduction in thrombotic events in most patient populations 1. Research demonstrates that even in high-risk patients with mechanical valves, standardized enoxaparin bridging can be safe when properly dosed and timed 11, 12.